Page 1,250«..1020..1,2491,2501,2511,252..1,2601,270..»

Lack of UK cell and gene therapy skills a concern – Bioprocess Insider – BioProcess Insider

Posted: December 2, 2019 at 9:45 am

UK cell and gene therapy firms are worried a shortage of skilled manufacturing staff will slow growth with some concerned Brexit will exacerbate the problem.

The findings come from a new skills survey by the Cell and Gene Therapy Catapult (CGTC) an organisation set up to support the sector by non-departmental government body, Innovate UK.

Of the 41 companies that responded, 98% said they planned to expand their headcount over the next five years. Of these, 83% raised concerns that hiring and retaining skilled staff will be an issue for growth.

Image: iStock/philhol

In addition, some respondents were concerned that Brexit will have a negative impact on recruiting and retaining skilled non-UK EU people according to the report.

More than 1,700 people are employed in bioprocessing roles in the UK cell and gene therapy sector, which is up from the 500 or so working in such positions in 2017. Based on this growth rate the CGTC expects 3,800 people will be working in such roles by 2024.

The survey also revealed 492 people are employed in cell and gene therapy manufacturing roles in the UK. This is expected to increase to 1,456 people up 196% by 2024. Respondents said finding staff with manufacturing skills as a substantial concern.

To address this, the report authors suggested cell and gene therapy firms would need to look beyond the sector.

The lack of talent will highly likely act as a brake to growth, with significant negative consequences on both organic and inward investment.

It is recommended, that companies are supported to deliver on their growth strategies, through the provision of supportive schemes, to both upskill their existing workforce as well as recruiting new talent, from outside of the sector.

The survey did not tally the number of EU nationals working in the UK cell and gene therapy sector or look at the potential impact Brexit would have on sectors ability to recruit.

However, a CGTC spokesperson told us We are confident that the UK cell and gene therapy industry will be able to source the necessary skills, and that the opportunities in research and training will remain attractive.

The spokesperson suggested overseas scientists continue to view the UK as attractive, adding We continue to see skilled people wanting to work in the UK sector from across the globe.

In addition, the spokesperson also expressed confidence cell and gene therapy developers would continue to see the UK as an attractive development and production base post withdrawal.

The supply chains for these advanced therapies are highly specialised and have been stringently developed in collaboration with medicine regulators to minimise any potential disruption.

There are already a number of advance therapies manufactured in the UK and exported seamlessly to the US for clinical trials and vice versa, we are confident that the movement of these therapies will remain unimpeded.

See the rest here:
Lack of UK cell and gene therapy skills a concern - Bioprocess Insider - BioProcess Insider

Posted in Cell Therapy | Comments Off on Lack of UK cell and gene therapy skills a concern – Bioprocess Insider – BioProcess Insider

Trial cancer treatment in Wichita – KAKE

Posted: December 2, 2019 at 9:43 am

WICHITA, Kan. (KAKE) -

There's a major medical break-through in the world of cancer treatment. No more chemotherapy or radiation; doctors in Wichita are using patients' own blood cells to fight off cancer, and it's working.

62-year-old David Butler's appointments at the Cancer Center of Kansas are coming to an end. It's been two long years for him - in 2017, stomach pain led doctors to discover 13 tumors inside his abdomen. Butler went through months of chemotherapy, then stem cell therapy. But the cancer kept coming back.

The news could have been grim. But not for Butler. The Cancer Center of Kansas is one of just nine facilities in the nation chosen to participate in a study using the patient's own cells to fight off the disease.

It's called Car T-cell Therapy. A patient's own immune cells are harvested, then genetically modified and inserted back into the body. Those t-cells then search out and kill the cancer. And the Car T-cell Therapy can be given as outpatient treatment, with no hospital stay required.

David Butler is now cancer-free, and his doctors are hopeful the t-cells will continue to stave off the disease.

The Cancer Center of Kansas has treated two patients, and so far so good. Once the study is finished, doctors and the drug company will go to the FDA for full approval to use the therapy to treat cancer across the country.

Go here to see the original:
Trial cancer treatment in Wichita - KAKE

Posted in Kansas Stem Cells | Comments Off on Trial cancer treatment in Wichita – KAKE

253 miles in 4 hours: A Syracuse mans race for a lung transplant, and the angel who helped him – syracuse.com

Posted: December 1, 2019 at 8:48 pm

When the call came, Dimitri Georgiadis would have exactly four hours to hug his two sons, zip up his bag and motor 253 miles from Syracuse to Philadelphia.

If he wasted even 15 minutes, the donated lung would be gone.

Word spread quickly through St. Sophias Greek Orthodox Church community. Does anyone know a pilot?

Ted Limpert immediately said yes. Limpert is a Syracuse city court judge, handling every kind of charge from midnight mishaps to human trafficking.

Before that, he was a part-time fighter pilot one of the first to scramble into action when the planes hit the World Trade Center.

Hes flown 2,200 hours in an F-16 and 750 hours in the A-10 Warthog as a member of the 174th Air National Guard fighter wing.

It was Limpert who flew a jet over Clinton Square, cracking the silence on the first anniversary of the Sept. 11, 2001 attacks.

He has retired from the military, but he still owns an airplane, parked at a small airport in Cortland.

This was the plan: Limpert would collect Georgiadis and his wife Eleni, drive to his plane, fly about an hour to the North Philadelphia airport. They would get a car, even if it meant calling an ambulance, and drive through Philadelphia traffic to Temple University Hospital, where a donated lung would be waiting to replace the ones threatening Georgiadis life.

It would just be another mission, he thought.

We called it TOT, time over target, Limpert said. You can be early, but you cant be late.

Georgiadis, 55, was diagnosed with pulmonary fibrosis in 2006. As he got older, the disease grew more and more aggressive. He worked 18 years at Di Lauros Bakery in Syracuse. Then he went to work in the maintenance department, plowing snow and fixing faucets, for the Onondaga County Parks Department.

Georgiadis went on oxygen and disability. He moved up the list for a lung transplant. It would be done at Temple University Hospital, where he was being treated.

He was planning to drive himself to the hospital. Doctors said the call could come in the middle of the night, when accidents are most likely to claim the lives of donors.

It would be a stretch for a man on oxygen and in shock to make it over the foggy hills of Pennsylvania, through Philadelphia traffic and to the hospital in time.

Eleni Georgiadis started making phone calls.

All summer, I was calling different pilots, she said. Everybody we called, they said they couldnt guarantee me. They said well put you on the list, but we cant guarantee.

Even when she offered to pay, there was no guarantee, she said.

Then, a friend from church asked a friend of Limperts for help. The families were strangers.

He said Absolutely, Eleni Georgiadis said.

For two months, Limpert kept the car gassed up. He constantly checked weather conditions. He carried his phone everywhere, to the bench and to bed.

If he left town, he texted Eleni Georgiadis.

When hed come back, hed say Green Light. Your pilot is here. Ready for call, she said.

On Monday, Nov. 18, Limpert checked the weather one more time before heading for bed. It didnt look good.

At about 9 p.m., the call came.

He had not packed an overnight bag, even though his wife told him to. She handed him a Red Bull and he was out the door.

There was too much fog, they would have to drive to Philadelphia.

Limpert typed the hospitals address into his GPS app. It said the arrival time was 1:06 a.m.

That would be too late.

Limpert, a judge, declined to put a number on his speed down I-81, through Scranton and onto I-76.

I was proceeding with traffic, he said, laughing.

But there was no traffic, he said.

Limpert had thought to consult with police officer friends in advance and he was ready to call in the state police for an escort, if necessary.

In the two months leading up to the call, Limpert got to know the Georgiadises. He invited the couple to the Cortland Airport to introduce them to his airplane.

They climbed into the four-seater Mooney, tried on the headsets, made sure they were up for a noisy and bumpy ride. Other times, they shared Sunday dinner, homemade baklava, calzones and stories. They talked about their Greek heritage and their children.

Heres what Limpert did not say:

He had his own type of transplant last year.

In January 2018, a doctor at the VA Medical Center noticed elevated protein levels during a routine blood check and referred him to an oncologist. The eventual diagnosis: Multiple myeloma.

Limpert did six months of chemotherapy with so few side effects, he kept it a secret from his children and colleagues. By July, he couldnt hide the treatment any longer. He needed a stem cell transplant.

Doctors at Upstate Medical University harvested 17 million cells, then pushed 5 million of them back into his body. He was in the hospital for two weeks. The rest are in the bank for future treatment.

On the late night drive to Philadelphia, Limpert thought about his own illness, the way he relied on others to pull him through.

In the car, he encouraged the couple to focus on the 10-to-12-hour surgery they faced.

I didnt tell them, Limpert said. I thought they needed to focus on their own health issues.

The GPS sent the three on a ride down the Schuylkill Expressway a highway that often functions more like a parking lot. Limpert took the risk.

We pulled in at 12:43 a.m., Limpert said. We still had 15 minutes to spare.

The lung patient, his wife and their fighter pilot took a selfie. The Georgiadises rushed into the hospital.

Limpert looked at the can of Red Bull unopened in his car. He decided to drive back to Syracuse.

Limpert arrived in his office for arraignments by 9 a.m. Every wall in his chamber has a photo or drawing of a fighter jet. There are commendations and photos from the seven times he was deployed to Southwest Asia, starting with Operation Desert Storm and ending with Operation Enduring Freedom.

This was pretty easy, he said.

Georgiadis surgery was a success.

So far, so good, he said in an interview Tuesday from the hospital. He will be in the hospital for at least two months. He expressed a tearful thank you to the donor, whose identity is not known. They will write a letter to the donors family to see if they want to connect and share their stories.

In the past week, they have stayed in constant touch with Limpert, who they now consider family.

He took a huge burden off our shoulder, Dimitri Georgiadis said. The biggest one ever.

In Greek, Theodore means The Gift of God, Eleni Georgiadis said.

We call Ted our angel, she said.

Contact the author: Michelle Breidenbach | mbreidenbach@syracuse.com | 315-470-3186.

Thanks for visiting Syracuse.com. Quality local journalism has never been more important, and your subscription matters. Not a subscriber yet? Please consider supporting our work.

Read more:
253 miles in 4 hours: A Syracuse mans race for a lung transplant, and the angel who helped him - syracuse.com

Posted in Pennsylvania Stem Cells | Comments Off on 253 miles in 4 hours: A Syracuse mans race for a lung transplant, and the angel who helped him – syracuse.com

Head to Head Survey: BioRestorative Therapies (OTCMKTS:BRTX) & Livongo Health (OTCMKTS:LVGO) – Mitchell Messenger

Posted: December 1, 2019 at 8:48 pm

Livongo Health (NASDAQ:LVGO) and BioRestorative Therapies (OTCMKTS:BRTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Insider and Institutional Ownership

18.4% of Livongo Health shares are owned by institutional investors. 17.9% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

This table compares Livongo Health and BioRestorative Therapies net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Livongo Health and BioRestorative Therapies top-line revenue, earnings per share (EPS) and valuation.

BioRestorative Therapies has lower revenue, but higher earnings than Livongo Health.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Livongo Health and BioRestorative Therapies, as provided by MarketBeat.com.

Livongo Health currently has a consensus price target of $44.30, suggesting a potential upside of 55.11%. Given Livongo Healths higher probable upside, equities analysts plainly believe Livongo Health is more favorable than BioRestorative Therapies.

Summary

Livongo Health beats BioRestorative Therapies on 7 of the 10 factors compared between the two stocks.

Livongo Health Company Profile

Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.

Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.

Read the original post:
Head to Head Survey: BioRestorative Therapies (OTCMKTS:BRTX) & Livongo Health (OTCMKTS:LVGO) - Mitchell Messenger

Posted in Pennsylvania Stem Cells | Comments Off on Head to Head Survey: BioRestorative Therapies (OTCMKTS:BRTX) & Livongo Health (OTCMKTS:LVGO) – Mitchell Messenger

World AIDS Day 2019: Theme, History and Facts about HIV and AIDS – Newsweek

Posted: December 1, 2019 at 8:46 pm

World AIDS Day is taking place on December 1 to raise awareness around HIV and AIDS, and to support the 37.9 million people around the world living with the virus.

This year's theme will be "Ending the HIV/AIDS Epidemic: Community by Community," highlighting the role of communities in preventing, treating and supporting people with HIV.

"I believe in communities," UNAIDS executive director Winnie Byanyima said in a statement. "Communities make change happen."

"With communities in the lead and governments living up to their promises, we will end AIDS."

Read more

This year marks the 21st World AIDS Day since its establishment in 1988, when James W. Bunn and Thomas Nettertwo public health officers at the World Health Organization's Global Program on AIDS in Genevaco-founded the day in an effort to destigmatize the disease.

"There was a lot that people felt they did not know about the epidemic and they were afraid," Bunn told NPR in a 2011 interview. "In those days people were being fired from their job. They were being denied Social Security benefits. They were being ostracized by their families. They were being evicted from their homes because they were sick and dying."

Today, people can show their support for people living with HIV and AIDS by donning a red ribbon.

HIV stands for human immunodeficiency virus, a condition that weakens the immune system against infections and certain cancers by destroying or impairing the body's immune cells.

If an HIV-positive person does not receive treatment, they could be susceptible to diseases and infections a person with a functioning immune system would be able to fight off, includingbut not limited totuberculosis and cryptococcal meningitis.

AIDS, which stands for acquired immune deficiency syndrome, is the most advanced stage of HIV and can develop any time between two and 15 years after infection if the person is not taking proper medication.

To qualify as AIDS, one of more than 20 life-threatening cancers or so-called "opportunistic infections" (such as Kaposi sarcoma, Non-Hodgkin lymphoma and cervical cancer) must be present, according to the WHO.

One important difference between the two is that HIV can be passed on from one person to another, while AIDS cannot.

HIV can be traced to chimpanzees in Central Africamost likely, Kinshasa, the capital of the Democratic Republic of the Congo (DRC), says Avert, an international HIV and AIDS charity based in the U.K. Scientists believe it is a mutation of simian immunodeficiency virus (SIV)a condition found in monkeys and apesthat was passed onto humans when hunters looking for bush meat came into contact with infected blood.

The theory is backed up by the fact that there are different strains of HIV (M, N, O, and P), suggesting slightly different forms of the virus emerged after multiple contact with SIV-carrying primates.

While scientists may not have identified the virus that caused AIDS until 1984, the jump from chimpanzee to human may have taken place much earlier and as far back as the late 1800s, according to the U.S. Centers for Disease Prevention and Control (CDC). The first confirmed case of HIV is from a sample of blood that was taken in 1957 and belonged to a man in Kinshasa.

From Kinshasa it spread through roads, railways and a burgeoning sex trade to other parts of the DRC and, by the 1960s, to Haiti. Many Haitians had been working in the DRC and it is thought that it is through them that HIV first traveled across the Atlantic to the Caribbean.

AIDS was not formally recognized until the early 1980s, when University of California, Los Angeles (UCLA) physician Michael Gottlieb put a name to a devastating illness affecting gay men living in Los Angeles. However, the first AIDS-related deaths in the U.S. are thought to have occurred much earlier.

On May 15, 1969, a gay black teenager died of a then-unknown illness in St Louis, Missouri. Before his death, 16 year old Robert Rayford had developed Kaposi sarcoma lesions and other AIDS related symptoms. However, it was not until 1987 that an autopsy revealed Rayford carried the virus and he is now believed to be the first person to have died from AIDS in the U.S.

It is not known who gave Rayford the disease but scientists now suspect that the virus entered and re-entered the U.S. several times, subsiding if there was not a large enough population for it to spread.

Recently, scientists have traced an unknown patient zero to early 1970s New York. It is thought the virus entered the U.S. from the Caribbean, gaining a foothold in New York before spreading to the rest of the country.

Worldwide, approximately 1.7 million people were newly infected with HIV last year. That includes 37,832 people in the U.S and associated territories.

In East and Southern Africa, where 7 percent of the population aged 15 to 49 are HIV-positive, there were 800,000 new infections in 2018.

HIV-1 Group M is the strain responsible for most of these.

According to government data, there are around 1.1 million people living with HIV in the U.S. today. Approximately 1 in 7 (or 15 percent) are unaware that they are infected.

Florida, Georgia and Louisiana are the states with the highest rates of infection per 100,000 people, the CDC reveals. As many 46 percent of people who are HIV-positive people live in Southern states.

However, the number of people newly diagnosed is decreasing. Overall, the number of people in the U.S. being diagnosed with HIV decreased around 9 percent between 2010 and 2016.

HIV is transmitted from one person to another through bodily fluids, including blood, breast milk and semen.

In the U.S., two-thirds of new diagnoses in 2018 were because of male-to-male intercourse. Around a quarter were caused by heterosexual intercourse and 7 percent were caused by drug injections using infected needles.

There are plenty of myths about how you can contract HIV. You cannot get AIDS from a toilet seat. Despite urban legends stating otherwise, HIV cannot be passed on to another person through hugging, shaking hands or sharing objects and/or food. As the CDC makes clear, the virus is not present in saliva (or tears or sweat) so unless both people have bleeding gums, it is not possible to get HIV from kissing.

Nobut it can be effectively managed.

According to the WHO, around 32 million people have died of AIDS. Fortunately, with the right treatment, an HIV-positive status is not a death sentence.

The average life expectancy in the U.S. for people without HIV is 76 years for men and 81 years for women. According to WebMD, a 20 year old who began antiretroviral treatment in 2008 and manages to maintain a low viral load can expect to live to around 78.

According to the WHO, 62 percent of people have received treatment and more than half (53 percent) have achieved HIV suppression so that there is effectively no risk of passing the virus on to others.

Timothy Ray Brown is a patient in Berlin who was apparently cured of HIV after undergoing a rigorous treatment to cure his acute myeloid leukemia.

The process effectively wiped out his immune system with large quantities of radiation or chemotherapy, and replaced it with stem cells from a donor.

The same treatment has been performed more recently in a London patient, who like Brown received donor cells from a person with two copies of a gene mutation affecting the CCR5 receptora mutation that effectively renders the person immune to HIV.

However, while testing might suggest the patients are in remission, experts have been careful about bandying around the word "cured." What's more, it can only be used to people who are HIV-positive and have acute myeloid leukemia.

Read more:
World AIDS Day 2019: Theme, History and Facts about HIV and AIDS - Newsweek

Posted in Florida Stem Cells | Comments Off on World AIDS Day 2019: Theme, History and Facts about HIV and AIDS – Newsweek

Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment – The Sun

Posted: December 1, 2019 at 8:46 pm

THIS is the heartbreaking moment a tiny toddler sobs her way through agonising cancer treatment.

Sophia Soto's devastated mum took the photo while her little 14-month-old was having a lead put on her chest.

13

Sophia was diagnosed with stage 4 neuroblastomaafter tumours were discovered behind her eyes and on her kidney.

And her mum Rosie, 40, is now sharing the harrowing image in a bid to highlight the traumatic reality of childhood cancer.

Speaking about the poignant picture, Rosie, from Florida, USA, said: "The picture of Sophia upset really does home in on the reality of childhood cancer.

"She was having a lead put on her chest for her treatment - which she didn't want - hence why Sophia was so upset.

13

13

"I look back at the picture now and wonder how I did it; it was so hard watching my little girl so ill."

Rosie first suspected something was wrong with Sophia after she began developing bruising around her eyes - something she claims doctors repeatedly dismissed as being from bump or fall.

It wasn't until Rosie took Sophia to see an eye specialist that they spotted what they suspected tumours behind her eyes were causing the bruising.

Rosie added: "Sophia kept getting bruising on her eyes and I didn't recall her falling over or anything, so I didn't understand where they were come from.

13

13

"I kept taking her to the doctors because the bruising wasn't going away, but they just said it must have been from a bump or something.

"Sophia wasn't referred for a scan or biopsy until I went to see an eye specialist with her who knew straight away that it was caused by a tumour.

"She was sent for an MRI where black spots appeared on the scans confirming the tumours behind her eyes.

"It was then the biopsy which found the tumours on one of her kidneys as well which led to her stage 4 neuroblastoma diagnosis."

Neuroblastoma is a rare type of cancer that mostly affects babies and children and develops from specialised nerve cells left behind from a baby's development in the womb.

I kept taking her to the doctors because the bruising wasn't going away, but they just said it must have been from a bump or something

After being diagnosed in March 2014, the then 14-month-old endured 60 rounds of chemotherapy, 20 rounds of radiation and a stem cell transplant over a six months period.

Thankfully, Sophia, now six, has been in remission for five years and now looks like a completely different child compared to the one in the heart wrenching photograph.

She was told she was in remission in November 2014 and has been medication free for two years.

Sophia isn't yet classified as 'cancer free' so still goes for check ups every six months with specialists.

What are the symptoms of cancer in children?

Cancer symptoms can be very similar to those of other childhood illnesses - and they vary between children.

According toCancer Research UK, there are 15 signs to look out for:

13

13

The brave six-year-old still has tumours behind her eyes which cannot be removed due to the placement of them, but doctors believe the tumours are benign and therefore not causing Sophia too much harm.

Rosie added: "Doctors are reluctant to remove the tumours Sophia currently has behind her eyes as they've said it would be likely the surgery to disfigure her face.

"Whilst they are tumours, doctors are reasonably confident that they are not cancerous so we have decided to not have the surgery right now, but it may be something she has when she's older."

13

13

Sophia now looks like any other fun-loving child and from her appearance, you would never know she had cancer.

The six-year-old loves to dance and hopes of becoming a vet one day.

Rosie said: "No one can imagine what she went through looking at her now - she just looks like a normal regular child.

"Sophia has her moments when she asks about when she was sick and has questions about her treatment scars, but over all she's a pretty happy girl.

13

13

13

Comment

DEBORAH JAMES I've got cancer-induced insomnia and it's breaking me physically and mentally

SURGE IN CASES Every 90 secs someone is told they have cancer - 10 signs you need to know

Warning

PRISONER IN MY HOME I live like a vampire after cancer ate my nose as I worry I scare kids

DIY SOS Prostate cancer home pee test 'detects it 5 years earlier & could save thousands'

LAST HOPE I've got months to live after dismissing terminal cancer as a niggling cough

OUT OF TIME Mum died 3 hours before my wedding after I brought it forward so she'd be there

MISSED CHANCES Docs said our little girl was 'attention seeking' but it was a brain tumour

NAIL IT The 'diamond gap' finger test that could be an early warning sign of lung cancer

BRIDE'S DREAM Cancer-stricken bride had arm amputated to have enough time to get married

"If I was to say anything to other parents with children battling cancer, I'd say to them to not give up, stay positive and keep your faith.

"It's really important not to compare your child's process to anyone else as everyone battles illnesses differently as every situation is different.

"We're over the moon that Sophia is now doing so well - we're really blessed that she's such a fighter."

13

Read the original:
Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment - The Sun

Posted in Florida Stem Cells | Comments Off on Mum shares heartbreaking photo of toddler sobbing through gruelling cancer treatment – The Sun

9 experts receive Faces of Biotechnology award – Business Mirror

Posted: November 30, 2019 at 4:46 pm

The Filipino Faces of Biotechnology award is bestowed on nine scientists, educators and science communicators during its fourth annual event held by the Department of Agriculture at a hotel in Makati on November 26.

The event is part of the weeklong National Biotechnology Week celebration. This years awardees are: Dr. Nathaniel Dugos, Outstanding researcher in bioengineering; Dr. Ernelea Cao, Outstanding educator, researcher and advocate on biotechnology; Dr. Candida Adalla, Outstanding leader in pioneering developmental initiatives for biotechnology; Dr. Gisela Concepcion, Outstanding researcher on medical and cosmetics through biotechnology; Dr. Milagros Greif, Outstanding researcher on urban pest control through biotechnology; Dr. Cynthia Hedreyda, Outstanding advocate for biotechnology education; Dr. Gabriel Romero, Outstanding researcher on rice genetics and crop biotechnology; the late Dr. Monina Villena, Outstanding science communicator for biotechnology (her husband, Nathaniel Villena, receives the award); and Dr. Claro Mingala, Outstanding livestock biotechnologist. They are joined by DA-Bureau of Agricultural Research Assistant Director Digna Sandoval (left), Agriculture Undersecretary Rodolfo Vicerra (second from right) and DA Biotechnology Program Office Director Dr. Dionisio Alvindia.

Photo by Lyn Resurreccion

Go here to see the original:
9 experts receive Faces of Biotechnology award - Business Mirror

Posted in Biotechnology | Comments Off on 9 experts receive Faces of Biotechnology award – Business Mirror

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? – Yahoo Finance

Posted: November 30, 2019 at 4:46 pm

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Dynamic Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.

An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transparency, flexibility, and tax efficiency; they are also excellent vehicles for long term investors.

Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 3, placing it in top 19%.

Index Details

The fund is sponsored by Invesco. It has amassed assets over $233.71 M, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses.

This is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.

Costs

Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio.

Annual operating expenses for this ETF are 0.57%, making it on par with most peer products in the space.

Sector Exposure and Top Holdings

Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.

Looking at individual holdings, Biogen Inc (BIIB) accounts for about 6.28% of total assets, followed by Vertex Pharmaceuticals Inc (VRTX) and Neurocrine Biosciences Inc (NBIX).

The top 10 holdings account for about 50.41% of total assets under management.

Performance and Risk

Year-to-date, the Invesco Dynamic Biotechnology & Genome ETF has added roughly 17.18% so far, and it's up approximately 7.20% over the last 12 months (as of 11/27/2019). PBE has traded between $43.44 and $56.26 in this past 52-week period.

The ETF has a beta of 1.43 and standard deviation of 22.73% for the trailing three-year period, making it a high risk choice in the space. With about 29 holdings, it has more concentrated exposure than peers.

Alternatives

Invesco Dynamic Biotechnology & Genome ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PBE is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Nasdaq Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $4.20 B in assets, iShares Nasdaq Biotechnology ETF has $7.54 B. XBI has an expense ratio of 0.35% and IBB charges 0.47%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportInvesco Dynamic Biotechnology & Genome ETF (PBE): ETF Research ReportsiShares Nasdaq Biotechnology ETF (IBB): ETF Research ReportsSPDR S&P Biotech ETF (XBI): ETF Research ReportsVertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis ReportBiogen Inc. (BIIB) : Free Stock Analysis ReportNeurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

See the original post here:
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? - Yahoo Finance

Posted in Biotechnology | Comments Off on Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? – Yahoo Finance

Where Does MRTX Stock Rank in the Biotechnology Industry? – InvestorsObserver

Posted: November 30, 2019 at 4:46 pm

The 57 rating InvestorsObserver gives to Mirati Therapeutics Inc (MRTX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 75 percent of stocks in the Biotechnology industry, MRTXs 57 overall rating means the stock scores better than 57 percent of all stocks.

Click Here to get the full Stock Score Report on Mirati Therapeutics Inc (MRTX) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 57 means the stock is more attractive than 57 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Mirati Therapeutics Inc (MRTX) stock has risen 0.91% while the S&P 500 is lower by -0.23% as of 11:07 AM on Friday, Nov 29. MRTX is up $0.90 from the previous closing price of $99.44 on volume of 61,363 shares. Over the past year the S&P 500 is up 14.93% while MRTX is up 168.50%. MRTX lost -$4.69 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more from the original source:
Where Does MRTX Stock Rank in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does MRTX Stock Rank in the Biotechnology Industry? – InvestorsObserver

Where Does CLVS Stock Rank in the Biotechnology Industry? – InvestorsObserver

Posted: November 30, 2019 at 4:46 pm

Clovis Oncology Inc (CLVS) is near the top in its industry group according to InvestorsObserver. CLVS gets an overall rating of 60. That means it scores higher than 60 percent of stocks. Clovis Oncology Inc gets a 79 rank in the Biotechnology industry. Biotechnology is number 84 out of 148 industries.

Click Here to get the full Stock Score Report on Clovis Oncology Inc (CLVS) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Clovis Oncology Inc (CLVS) stock is up 14.18% while the S&P 500 is down -0.23% as of 11:06 AM on Friday, Nov 29. CLVS has gained $1.76 from the previous closing price of $12.41 on volume of 16,936,555 shares. Over the past year the S&P 500 has risen 14.93% while CLVS is down -17.62%. CLVS lost -$7.51 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

See the original post:
Where Does CLVS Stock Rank in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does CLVS Stock Rank in the Biotechnology Industry? – InvestorsObserver

Page 1,250«..1020..1,2491,2501,2511,252..1,2601,270..»